{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T17:28:13Z","timestamp":1748280493945,"version":"3.37.3"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2017,4,4]],"date-time":"2017-04-04T00:00:00Z","timestamp":1491264000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2017,7]]},"DOI":"10.1007\/s40261-017-0520-5","type":"journal-article","created":{"date-parts":[[2017,4,5]],"date-time":"2017-04-05T04:10:53Z","timestamp":1491365453000},"page":"647-657","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Exposure\u2013Safety Response Relationship for Ombitasvir, Paritaprevir\/Ritonavir, Dasabuvir, and Ribavirin in Patients with Chronic Hepatitis C Virus Genotype 1 Infection: Analysis of Data from Five Phase II and Six Phase III Studies"],"prefix":"10.1007","volume":"37","author":[{"given":"Chih-Wei","family":"Lin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rajeev","family":"Menon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Podsadecki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nancy","family":"Shulman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"DaSilva-Tillmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Walid","family":"Awni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandeep","family":"Dutta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,4,4]]},"reference":[{"issue":"2","key":"520_CR1","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1053\/j.gastro.2014.04.045","volume":"147","author":"P Andreone","year":"2014","unstructured":"Andreone P, Colombo MG, Enejosa JV, et al. ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatment-experienced patients with HCV genotype 1b infection. Gastroenterology. 2014;147(2):359\u2013365.e1.","journal-title":"Gastroenterology"},{"issue":"17","key":"520_CR2","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1056\/NEJMoa1315722","volume":"370","author":"JJ Feld","year":"2014","unstructured":"Feld JJ, Kowdley KV, Coakley E, et al. Treatment of HCV with ABT-450\/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med. 2014;370(17):1594\u2013603.","journal-title":"N Engl J Med"},{"issue":"21","key":"520_CR3","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1056\/NEJMoa1402338","volume":"370","author":"P Ferenci","year":"2014","unstructured":"Ferenci P, Bernstein D, Lalezari J, et al. ABT-450\/r-ombitasvir and dasabuvir with or without ribavirin for HCV. N Engl J Med. 2014;370(21):1983\u201392.","journal-title":"N Engl J Med"},{"issue":"21","key":"520_CR4","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1056\/NEJMoa1402869","volume":"370","author":"F Poordad","year":"2014","unstructured":"Poordad F, Hezode C, Trinh R, et al. ABT-450\/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med. 2014;370(21):1973\u201382.","journal-title":"N Engl J Med."},{"issue":"17","key":"520_CR5","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1056\/NEJMoa1401561","volume":"370","author":"S Zeuzem","year":"2014","unstructured":"Zeuzem S, Jacobson IM, Baykal T, et al. Retreatment of HCV with ABT-450\/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med. 2014;370(17):1604\u201314.","journal-title":"N Engl J Med"},{"issue":"5","key":"520_CR6","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1517\/14656566.2014.889116","volume":"15","author":"AF Carrion","year":"2014","unstructured":"Carrion AF, Gutierrez J, Martin P. New antiviral agents for the treatment of hepatitis C: ABT-450. Expert Opin Pharmacother. 2014;15(5):711\u20136.","journal-title":"Expert Opin Pharmacother"},{"issue":"S1","key":"520_CR7","first-page":"244A","volume":"58","author":"E Lawitz","year":"2013","unstructured":"Lawitz E, Hezode C, Varunok P, et al. Interferon- and ribavirin-free regimen of ABT-450\/r + ABT-267 in HCV genotype 1b-infected treatment-naive patients and prior null responders. Hepatology. 2013;58(S1):244A.","journal-title":"Hepatology"},{"issue":"S1","key":"520_CR8","first-page":"1129A","volume":"60","author":"S Pol","year":"2014","unstructured":"Pol S, Reddy KR, Baykal T, et al. Interferon-free regmens of ombitasvir and ABT-450\/r with or without ribavirin in patients with HCV genotype 4 infection: PEARL-I study results. Hepatology. 2014;60(S1):1129A.","journal-title":"Hepatology"},{"key":"520_CR9","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1002\/hep.27972","volume":"62","author":"HCK Kumada","year":"2015","unstructured":"Kumada HCK, Rodrigues L Jr, Suzuki F, et al. Randomized phase 3 trial of ombitasvir\/paritaprevir\/ritonavir for hepatitis C virus genotype 1b-infected Japanese patients with or without cirrhosis. Hepatology. 2015;62:1037\u201346.","journal-title":"Hepatology"},{"issue":"9986","key":"520_CR10","doi-asserted-by":"crossref","first-page":"2502","DOI":"10.1016\/S0140-6736(15)60159-3","volume":"385","author":"C Hezode","year":"2015","unstructured":"Hezode C, Asselah T, Reddy KR, et al. Ombitasvir plus paritaprevir plus ritonavir with or without ribavirin in treatment-naive and treatment-experienced patients with genotype 4 chronic hepatitis C virus infection (PEARL-I): a randomised, open-label trial. Lancet. 2015;385(9986):2502\u20139.","journal-title":"Lancet"},{"issue":"3","key":"520_CR11","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1056\/NEJMoa1306227","volume":"370","author":"KV Kowdley","year":"2014","unstructured":"Kowdley KV, Lawitz E, Poordad F, et al. Phase 2b trial of interferon-free therapy for hepatitis C virus genotype 1. N Engl J Med. 2014;370(3):222\u201332.","journal-title":"N Engl J Med"},{"issue":"2","key":"520_CR12","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.jinf.2014.09.008","volume":"70","author":"E Lawitz","year":"2015","unstructured":"Lawitz E, Sullivan G, Rodriguez-Torres M, et al. Exploratory trial of ombitasvir and ABT-450\/r with or without ribavirin for HCV genotype 1, 2, and 3 infection. J Infect. 2015;70(2):197\u2013205.","journal-title":"J Infect"},{"issue":"1","key":"520_CR13","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1208809","volume":"368","author":"F Poordad","year":"2013","unstructured":"Poordad F, Lawitz E, Kowdley KV, et al. Exploratory study of oral combination antiviral therapy for hepatitis C. N Engl J Med. 2013;368(1):45\u201353.","journal-title":"N Engl J Med"},{"issue":"2","key":"520_CR14","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.jhep.2015.03.029","volume":"63","author":"J Lalezari","year":"2015","unstructured":"Lalezari J, Sullivan JG, Varunok P, et al. Ombitasvir\/paritaprevir\/r and dasabuvir plus ribavirin in HCV genotype 1-infected patients on methadone or buprenorphine. J Hepatol. 2015;63(2):364\u20139.","journal-title":"J Hepatol"},{"key":"520_CR15","doi-asserted-by":"crossref","unstructured":"Epstein M, Felizarta F, Marbury T, et al. Study of ABT-267 2-day monotherapy followed by 12-week combination therapy in treatment-naive patients with chronic HCV genotype 1 infection. J Hepatol. 2013;58(Suppl.):S484.","DOI":"10.1016\/S0168-8278(13)61191-5"},{"issue":"4","key":"520_CR16","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1002\/cpdd.246","volume":"5","author":"AR Polepally","year":"2016","unstructured":"Polepally AR, Dutta S, Hu B, et al. Drug\u2013drug interaction of omeprazole with the HCV direct-acting antiviral agents paritaprevir\/ritonavir and ombitasvir with and without dasabuvir. Clin Pharmacol Drug Dev. 2016;5(4):269\u201377.","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"1","key":"520_CR17","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1208\/s12248-015-9846-1","volume":"18","author":"S Mensing","year":"2016","unstructured":"Mensing S, Polepally AR, Konig D, et al. Population pharmacokinetics of paritaprevir, ombitasvir, dasabuvir, ritonavir, and ribavirin in patients with hepatitis C virus genotype 1 infection: combined analysis from 9 phase 1b\/2 studies. AAPS J. 2016;18(1):270\u201380.","journal-title":"AAPS J"},{"issue":"Suppl. 2","key":"520_CR18","doi-asserted-by":"crossref","first-page":"S644","DOI":"10.1016\/S0168-8278(15)31023-0","volume":"62","author":"S Mensing","year":"2015","unstructured":"Mensing S, Sharma S, Eckert D, et al. Pharmacokinetics of paritaprevir, ombitasvir, dasabuvir, ritonavir and ribavirin in subjects with HCV genotype 1 infection in phase 3 studies. J Hepatol. 2015;62(Suppl. 2):S644.","journal-title":"J Hepatol"},{"issue":"8","key":"520_CR19","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1046\/j.1365-2036.1998.00359.x","volume":"12","author":"JA Moreno-Monteagudo","year":"1998","unstructured":"Moreno-Monteagudo JA, Fernandez-Bermejo M, Garcia-Buey L, et al. Interferon alpha with ribavirin for the treatment of chronic hepatitis C in non-responders or relapsers to interferon monotherapy. Aliment Pharmacol Ther. 1998;12(8):717\u201323.","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"520_CR20","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1002\/hep.510260231","volume":"26","author":"HC Bodenheimer Jr","year":"1997","unstructured":"Bodenheimer HC Jr, Lindsay KL, Davis GL, et al. Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: a multicenter trial. Hepatology. 1997;26(2):473\u20137.","journal-title":"Hepatology"},{"issue":"4","key":"520_CR21","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.bpg.2012.09.009","volume":"26","author":"B Maasoumy","year":"2012","unstructured":"Maasoumy B, Wedemeyer H. Natural history of acute and chronic hepatitis C. Best Pract Res Clin Gastroenterol. 2012;26(4):401\u201312.","journal-title":"Best Pract Res Clin Gastroenterol"},{"issue":"5","key":"520_CR22","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1046\/j.1365-2036.2003.01463.x","volume":"17","author":"SS Lee","year":"2003","unstructured":"Lee SS. Review article: indicators and predictors of response to anti-viral therapy in chronic hepatitis C. Aliment Pharmacol Ther. 2003;17(5):611\u201321.","journal-title":"Aliment Pharmacol Ther"},{"issue":"25","key":"520_CR23","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1056\/NEJM198612183152503","volume":"315","author":"JH Hoofnagle","year":"1986","unstructured":"Hoofnagle JH, Mullen KD, Jones DB, et al. Treatment of chronic non-A, non-B hepatitis with recombinant human alpha interferon. N Engl J Med. 1986;315(25):1575\u20138.","journal-title":"N Engl J Med"},{"key":"520_CR24","volume-title":"Viekira Pak (ombitasvir, paritaprevir, and ritonavir tablets; dasabuvir tablets): package insert","author":"AbbVie Inc.","year":"2016","unstructured":"AbbVie Inc. Viekira Pak (ombitasvir, paritaprevir, and ritonavir tablets; dasabuvir tablets): package insert. North Chicago: AbbVie Inc; 2016."},{"issue":"3","key":"520_CR25","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1517\/14740338.2014.884068","volume":"13","author":"E Ridruejo","year":"2014","unstructured":"Ridruejo E. Safety of direct-acting antivirals in the treatment of chronic hepatitis C. Expert Opin Drug Saf. 2014;13(3):307\u201319.","journal-title":"Expert Opin Drug Saf"},{"issue":"5","key":"520_CR26","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1111\/bcp.12873","volume":"81","author":"RM Menon","year":"2016","unstructured":"Menon RM, Klein CE, Podsadecki TJ, et al. Pharmacokinetics and tolerability of paritaprevir, a direct acting antiviral agent for hepatitis C virus treatment, with and without ritonavir in healthy volunteers. Br J Clin Pharmacol. 2016;81(5):929\u201340.","journal-title":"Br J Clin Pharmacol"},{"key":"520_CR27","unstructured":"Bow DAJ, Liu J, Kavetskaia O, et al. A mechanistic non-clinical assessment of drug-drug interactions (metabolism and transporters) with the hepatitis C virus (HCV) regimen: ABT-450\/r, ombitasvir and dasabuvir. AASLD\/EASL Special Conference on Hepatitis C, 3\u20135 Oct 2014, New York (NY)."},{"key":"520_CR28","unstructured":"Menon R, Badri P, Khatri A, et al. ABT-450\/ritonavir + ombitasvir + dasabuvir: drug interactions mediated by transporters. 15th International Workshop on Clinical Pharmacology of HIV and Hepatitis Therapy, 19\u201321 May 2014, Washington, DC."},{"issue":"13","key":"520_CR29","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1056\/NEJMoa1010494","volume":"364","author":"F Poordad","year":"2011","unstructured":"Poordad F, McCone J Jr, Bacon BR, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med. 2011;364(13):1195\u2013206.","journal-title":"N Engl J Med"},{"issue":"13","key":"520_CR30","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa1009482","volume":"364","author":"BR Bacon","year":"2011","unstructured":"Bacon BR, Gordon SC, Lawitz E, et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med. 2011;364(13):1207\u201317.","journal-title":"N Engl J Med"},{"issue":"25","key":"520_CR31","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1056\/NEJMoa1013086","volume":"364","author":"S Zeuzem","year":"2011","unstructured":"Zeuzem S, Andreone P, Pol S, et al. Telaprevir for retreatment of HCV infection. N Engl J Med. 2011;364(25):2417\u201328.","journal-title":"N Engl J Med"},{"issue":"25","key":"520_CR32","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1056\/NEJMoa1012912","volume":"364","author":"IM Jacobson","year":"2011","unstructured":"Jacobson IM, McHutchison JG, Dusheiko G, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med. 2011;364(25):2405\u201316.","journal-title":"N Engl J Med"},{"issue":"11","key":"520_CR33","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/j.amjmed.2008.07.012","volume":"121","author":"M Alleyne","year":"2008","unstructured":"Alleyne M, Horne MK, Miller JL. Individualized treatment for iron-deficiency anemia in adults. Am J Med. 2008;121(11):943\u20138.","journal-title":"Am J Med"},{"issue":"3","key":"520_CR34","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1093\/aje\/kwn355","volume":"169","author":"NA Zakai","year":"2009","unstructured":"Zakai NA, McClure LA, Prineas R, et al. Correlates of anemia in American blacks and whites: the REGARDS Renal Ancillary Study. Am J Epidemiol. 2009;169(3):355\u201364.","journal-title":"Am J Epidemiol"},{"issue":"6","key":"520_CR35","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1016\/j.jhep.2013.07.014","volume":"59","author":"M Romero-Gomez","year":"2013","unstructured":"Romero-Gomez M, Berenguer M, Molina E, Calleja JL. Management of anemia induced by triple therapy in patients with chronic hepatitis C: challenges, opportunities and recommendations. J Hepatol. 2013;59(6):1323\u201330.","journal-title":"J Hepatol"},{"issue":"2","key":"520_CR36","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1128\/AAC.04227-14","volume":"59","author":"T Pilot-Matias","year":"2015","unstructured":"Pilot-Matias T, Tripathi R, Cohen D, et al. In vitro and in vivo antiviral activity and resistance profile of the hepatitis C virus NS3\/4A protease inhibitor ABT-450. Antimicrob Agents Chemother. 2015;59(2):988\u201397.","journal-title":"Antimicrob Agents Chemother"},{"issue":"9","key":"520_CR37","doi-asserted-by":"crossref","first-page":"5445","DOI":"10.1128\/AAC.00998-15","volume":"59","author":"P Krishnan","year":"2015","unstructured":"Krishnan P, Tripathi R, Schnell G, et al. Resistance analysis of baseline and treatment-emergent variants in hepatitis C virus genotype 1 in the AVIATOR study with paritaprevir-ritonavir, ombitasvir, and dasabuvir. Antimicrob Agents Chemother. 2015;59(9):5445\u201354.","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40261-017-0520-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-017-0520-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-017-0520-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,15]],"date-time":"2017-06-15T05:33:26Z","timestamp":1497504806000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40261-017-0520-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4,4]]},"references-count":37,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2017,7]]}},"alternative-id":["520"],"URL":"https:\/\/doi.org\/10.1007\/s40261-017-0520-5","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"type":"print","value":"1173-2563"},{"type":"electronic","value":"1179-1918"}],"subject":[],"published":{"date-parts":[[2017,4,4]]}}}